Stemvac vaccine for triple-negative breast cancer with residual cancer
Part of Cancer, Skin clinical trials.
This trial tests a vaccine called STEMVAC to see if it can help people with triple-negative breast cancer who still have moderate or large amounts of cancer after chemotherapy. The vaccine is designed to help the immune system fight any remaining cancer cells and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have triple-negative breast cancer and finished standard chemotherapy before surgery.
- After surgery, your doctor determined you have moderate or extensive residual cancer (RCB index 2 or 3).
- You have not had a return of cancer locally or in other parts of the body.
- You are healthy enough to be up and about (ECOG score 0-2).
- Your blood counts and organ function are acceptable within 30 days before the first vaccine dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding a cancer vaccine (with GM-CSF) to standard HER2-targeted chemotherapy before surgery improves treatment outcomes for HER2-positive breast cancer. If you join, you’ll receive planned medicine before surgery to treat the tumor, then continue with the study schedule.
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
This trial tests a cancer vaccine called STEMVAC for people with advanced non-small cell lung cancer. The vaccine is given along with ongoing maintenance immunotherapy (pembrolizumab) to see if it can help keep the cancer from growing.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
Hear when a new Anatomic Stage I Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.